Status of Sancuso (SP-01) Product Sales
Filing company (Solasia Pharma K.K.)
Sancuso (SP-01) and new China sales partner MAAB
Certain documentation procedures related to the change in sales partner remain outstanding
USD1,299,240 (product sales proceeds, received; classification as revenue recognized in the consolidated statement of income: Not disclosed)
Third quarter of fiscal 2026
The matter will have no impact on the company's fiscal 2026 earnings forecast.
Related procedures
Certain documentation procedures related to the change in sales partner
Following completion of the outstanding documentation procedures, revenue is expected to be recognized in the consolidated statement of income in the third quarter of fiscal 2026.
| Item | Details |
|---|---|
| Event name | Status of Sancuso (SP-01) Product Sales |
| Subject Entity | Filing company (Solasia Pharma K.K.) |
| Target Locations / Products | Sancuso (SP-01) and new China sales partner MAAB |
| Cause | Certain documentation procedures related to the change in sales partner remain outstanding |
| Amount of Impact on Business Performance | USD1,299,240 (product sales proceeds, received; classification as revenue recognized in the consolidated statement of income: Not disclosed) |
| Accounting period in which recognized | Third quarter of fiscal 2026 |
| Impact on Earnings Forecast | The matter will have no impact on the company's fiscal 2026 earnings forecast. |
| Type of litigation or proceeding | Certain documentation procedures related to the change in sales partner |
| Outlook | Following completion of the outstanding documentation procedures, revenue is expected to be recognized in the consolidated statement of income in the third quarter of fiscal 2026. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Certain documentation procedures related to the change in sales partner remain outstanding.